Therapeutic Response

v::ROS1 status confers therapeutic sensitivity to Repotrectinib in patients with Non-Small Cell Lung Cancer.

Statements

Source and description
Augtyro (repotrectinib) [package insert]. FDA. The U.S. Food and Drug Administration granted approval to repotrectinib for the treatment of adult patients with locally advanced or metastatic ROS1-positive non-small cell lung cancer (NSCLC).
Augtyro (repotrectinib) [product information]. EMA. The European Medicines Agency (EMA) has authorized repotrectinib for the treatment of adult patients with ROS1-positive advanced non-small cell lung cancer (NSCLC).